News | March 20, 2012

GE Healthcare And BAC Collaborate To Launch New Bioprocess Affinity Resin

Source: Cytiva

LambdaFabSelect for purification of antibody fragments containing a lambda light chain

GE Healthcare, the healthcare business of GE and BAC BV, the leading provider of antibody-based affinity purification technology, announced recently that, following a successful collaboration between the two companies, GE Healthcare Life Sciences has added a new and innovative affinity resin to its portfolio of technologies for the purification of antibody-based fragments. GE Healthcare’s new resin, LambdaFabSelect, is a designed tool for the GMP-regulated purification of antibodies and antibody fragments that contain a lambda light chain. Antibody fragments are receiving increased attention as potential future biopharmaceuticals because, compared with monoclonal antibodies, they have a number of advantages such as improved tissue penetration and the ability to bind to targets inaccessible to conventional antigen-binding sites.

The launch of LambdaFabSelect follows the success of KappaSelect an affinity resin developed in an earlier collaboration between BAC and GE Healthcare. KappaSelect is designed for the purification of antibodies and antibody fragments containing the kappa light chain.

“Henrik Ihre, Director of Custom Design Media at GE Healthcare Life Sciences, said, “One of the key challenges in antibody and antibody fragment purification is to design resins that are highly-selective and can cover a broad range of different antibody formats. Collaborating with the team at BAC has resulted in a ready-to-use product for all human antibody formats containing a lambda light chain.”

“LambdaFabSelect enables bioprocess engineers to use BAC’s ligand technology to produce Fab fragments with a lambda light chain for clinical and commercial use. It provides greater flexibility in the purification of these important biotherapeutics”, added Laurens Sierkstra, CEO of BAC, “and complements the products we have already launched with GE Healthcare for antibody and antibody fragment purification, KappaSelect and IgSelect.”

About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems. Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company. Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries.

About BAC BV
BAC discovers, develops and manufactures separation and affinity purification products for use across the value chain of biopharmaceutical R&D and manufacturing. Based on BAC’s proprietary single-chain antibody technology called CaptureSelect, the products are suitable for the discovery, preclinical and clinical manufacturing of therapeutic proteins, including antibodies and antibody fragments. They enable a reduced time to market, increased purity and yield and an overall lower cost of goods for biopharmaceutical drug development. BAC BV was established in 1995 as a Unilever subsidiary and is collaborating with the leading life sciences vendors. Currently the Company employs 37 people with an R&D laboratory facility in Leiden and a state-of-the-art ISO 9001 certified manufacturing plant in Naarden, the Netherlands.

SOURCE: Cytiva